| Original language | English (US) |
|---|---|
| Pages (from-to) | 553-554 |
| Number of pages | 2 |
| Journal | ONCOLOGY (United States) |
| Volume | 35 |
| Issue number | 9 |
| DOIs | |
| State | Published - 2021 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: ONCOLOGY (United States), Vol. 35, No. 9, 2021, p. 553-554.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - The current molecular treatment landscape of advanced colorectal cancer and need for the COLOMATE Platform
AU - Ciombor, Kristen K.
AU - Jones, Jeremy C.
AU - Strickler, John
AU - Bekaii-Saab, Tanios S.
AU - Wu, Christina
N1 - Funding Information: FINANCIALDISCLOSURES: TY reports research grants from Amgen Inc; Funding Information: FUNDING SOURCE: This work is supported by the Department of Defense Prostate Cancer Research Program, Award No W81XWH-18-2-0013, W81XWH-18-2-0015, W81XWH-18-2-0016, W81XWH-18-2-0017, W81XWH-18-2-0018 and W81XWH-18-2-0019 Prostate Cancer Biorepository Network (PCBN). Funding Information: advisory roles with CytoLumina, Genentech/Roche, Janssen Oncology, Janssen, and Novartis; serves on Speakers’ Bureau for Bayer; receives research funding from Pfizer; holds patents on NanoVelcro Assay for CTCs in prostate cancer; and receives travel, accommodations, and expenses from TRACON Pharma. RF serves as leadership for 4Dx, and Apollomics, Inc; has consulting or advisory role with Bristol Myers Squibb, CBT Pharmaceuticals, and Johnson & Johnson, receives research funding from Bristol Myers Squibb (Inst), Calithera Biosciences (Inst), Exelixis (Inst), Merck (Inst), Peloton Therapeutics (Inst). JG has consulting or advisory roles with EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, and Janssen Pharmaceuticals, Inc.
PY - 2021
Y1 - 2021
UR - http://www.scopus.com/inward/record.url?scp=85116318712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116318712&partnerID=8YFLogxK
U2 - 10.46883/ONC.2021.3509.0553
DO - 10.46883/ONC.2021.3509.0553
M3 - Review article
C2 - 34524770
AN - SCOPUS:85116318712
SN - 0890-9091
VL - 35
SP - 553
EP - 554
JO - ONCOLOGY (United States)
JF - ONCOLOGY (United States)
IS - 9
ER -